|
Feb 27
|
Intellia Therapeutics, Inc. (NTLA) Reports Q4 Loss, Tops Revenue Estimates
|
|
Feb 27
|
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Company Progress
|
|
Feb 25
|
Praxis Precision Medicines, Inc. (PRAX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
|
|
Feb 14
|
Intellia Therapeutics (NTLA): Among The Small–Cap Stocks Insiders Are Selling Recently
|
|
Feb 14
|
Does Intellia Therapeutics (NTLA) Have the Potential to Rally 422.41% as Wall Street Analysts Expect?
|
|
Dec 30
|
Why Is Intellia Therapeutics, Inc. (NTLA) Among the Top CRISPR Stocks to Invest In?
|
|
Oct 17
|
Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
|
|
Oct 17
|
This Beaten-Down Growth Stock Could Skyrocket 234%, According to Wall Street
|
|
Oct 16
|
Is Intellia Therapeutics, Inc. (NTLA) the Most Promising Biotech Stock According to Hedge Funds?
|
|
Oct 10
|
Intellia Therapeutics Announces New Date for Upcoming Investor Webcast
|
|
Oct 9
|
Intellia Therapeutics Inc (NTLA) Q2 2024 Earnings Call Highlights: Strategic Advances and ...
|
|
Jul 26
|
Intellia (NTLA) to Report Q2 Earnings: What's in the Cards?
|
|
Jul 24
|
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
|
|
Jul 23
|
7 Biotech Stocks to Keep on Your Clinical Radar
|
|
Jun 27
|
Intellia (NTLA) Shares Fall as CFO Glenn Goddard Steps Down
|
|
Jun 26
|
Intellia Therapeutics Announces CFO Transition
|
|
Jun 26
|
First-of-its-kind Intellia data suggest CRISPR drug could be given more than once
|
|
Jun 25
|
Intellia Announces Positive Clinical Proof-of-Concept Data for Redosing a CRISPR-Based Therapy with its Proprietary LNP-Based Delivery Platform
|
|
Jun 21
|
Wall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for June 2024
|
|
Apr 12
|
Cathie Wood Goes Bargain Hunting. 2 Stocks She Bought This Week.
|